A study of the relationship between dasatinib medication for chronic myeloid leukemia in chronic phase and vascular endothelial function related and immunological parameters.

Phase 2

• Conditions: chronic myeloid leukemia

• Registration Number: JPRN-UMIN000006517
• Lead Sponsor: Kansai CML-Clinical Study Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-10-11
• Study Completion: 2014-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from this study 1) Presence of any other active neoplasm 2) Pregnant and lactating woman 3) Whom the investigator considered inappropriate to this study 4) Presence of apparent pleural effusion 5) Patients with complication or history of serious or poor-controlled cardiovascular disorders as below Cardiac infarction within 6 months Angina pectoris within 3 months Congestive heart failure within 3 months Suspicion of a congenital long QT syndrome QTc interval prolongation (adjusted according to Fridericia's formula) on the electrocardiogram exceed 450 msec at baseline

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Examine the relationship between occurrence of pleural effusion caused by dasatinib medication and levels of angiopoietin-2 in plasma.

Secondary Outcome Measures

Name	Time	Method
1) Examine the relationship between dasatinib medication and occurrence of pleural effusion by vascular endothelial function related parameters and by immunological parameters. 2) Examine the relationship between dasatinib medication and thrombocytopenia by vascular endothelial function related parameters and by immunological parameters.